Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance

Alexia Karen Cotte, Virginie Aires, Maxime Fredon, Emeric Limagne, Valentin Derangère, Marion Thibaudin, Etienne Humblin, Alessandra Scagliarini, Jean Paul Pais De Barros, Patrick Hillon, François Ghiringhelli, Dominique Delmas

Research output: Contribution to journalArticlepeer-review

197 Scopus citations


Lipid droplet (LD) accumulation is a now well-recognised hallmark of cancer. However, the significance of LD accumulation in colorectal cancer (CRC) biology is incompletely understood under chemotherapeutic conditions. Since drug resistance is a major obstacle to treatment success, we sought to determine the contribution of LD accumulation to chemotherapy resistance in CRC. Here we show that LD content of CRC cells positively correlates with the expression of lysophosphatidylcholine acyltransferase 2 (LPCAT2), an LD-localised enzyme supporting phosphatidylcholine synthesis. We also demonstrate that LD accumulation drives cell-death resistance to 5-fluorouracil and oxaliplatin treatments both in vitro and in vivo. Mechanistically, LD accumulation impairs caspase cascade activation and ER stress responses. Notably, droplet accumulation is associated with a reduction in immunogenic cell death and CD8+ T cell infiltration in mouse tumour grafts and metastatic tumours of CRC patients. Collectively our findings highlight LPCAT2-mediated LD accumulation as a druggable mechanism to restore CRC cell sensitivity.

Original languageEnglish
Article number322
JournalNature Communications
Issue number1
StatePublished - 1 Dec 2018
Externally publishedYes


Dive into the research topics of 'Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance'. Together they form a unique fingerprint.

Cite this